Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02103855 · ClinicalTrials.gov registry record · Phase 4
Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
A Phase 4 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT02103855: Completed Phase 4 study, sponsored by Indiana University.
NCT02103855 is a Phase 4 study that has completed, run by Indiana University. The registered enrollment target is 6 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02103855, a Phase 4 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
Kidney damage is a major complication of current antirejection medicines used in transplantation. An increasing number of brittle diabetics are successfully receiving a pancreas transplant. One of the challenges following pancreas transplant is that a patient can develop kidney damage from one of their antirejection medicines, tacrolimus. The objective of this study is to substitute a new antirejection medicine which does not cause kidney damage, belatacept for tacrolimus in patients that have developed signs of tacrolimus related kidney damage to slow the progression of kidney disease.
Primary Outcome
Change in serum eGFR from baseline to 1 year following conversion from tacrolimus to belatacept
Interventions
- DRUG Belatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-03 |
| Phase | Phase 4 |
What the finished NCT02103855 record still lists
NCT02103855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Belatacept is the first listed.
NCT02103855 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02103855 about?
NCT02103855 is a clinical study titled "Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients". Kidney damage is a major complication of current antirejection medicines used in transplantation. An increasing number of brittle diabetics are successfully receiving a pancreas transplant. One of the challenges following pancreas transplant is that a patient can develop kidney damage from one of th...
What is the current status of trial NCT02103855?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2014-06. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02103855?
The interventions under investigation include: Belatacept (DRUG).
Who is sponsoring clinical trial NCT02103855?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02103855's enrollment target sits among peer trials
6 1983rd of 2000 higher than 12 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia